MARKSANS.NS Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 13:00):

Marksans Pharma Limited, together with its subsidiaries, engages in the research and development, manufacturing, marketing, distribution, and sale of generic pharmaceutical formulations worldwide...

Stats
Šios dienos apimtis	2.11M
Vidutinė apimtis	1.87M
Rinkos kapitalizacija	78.01B
EPS	INR0 ( 2024-02-14 )
Kita pelno data	( INR0 ) 2024-05-27
Last Dividend	INR0.500 ( 2023-06-07 )
Next Dividend	INR0 ( N/A )
P/E	24.42
ATR14	INR0.256 (0.15%)

Tūris Koreliacija

Ilgas: 0.07 (neutral)

Trumpas: -0.23 (neutral)

Signal:(39.297) Neutral

Marksans Pharma Limited Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Marksans Pharma Limited Koreliacija - Valiuta/Žaliavos

0.02
( neutral )

-0.12
( neutral )

0.00
( neutral )

0.21
( neutral )

0.10
( neutral )

-0.43
( neutral )

Marksans Pharma Limited Finansinės ataskaitos

Annual	2022
Pajamos:	INR18.52B
Bruto pelnas:	INR9.31B (50.25 %)
EPS:	INR6.41

FY	2022
Pajamos:	INR18.52B
Bruto pelnas:	INR9.31B (50.25 %)
EPS:	INR6.41

FY	2022
Pajamos:	INR14.80B
Bruto pelnas:	INR7.32B (49.46 %)
EPS:	INR4.56

FY	2021
Pajamos:	INR13.68B
Bruto pelnas:	INR7.50B (54.79 %)
EPS:	INR5.83

Financial Reports:

No articles found.

Marksans Pharma Limited Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR0.250 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0.500 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Marksans Pharma Limited Dividend Information - Dividend Junior

Dividend Sustainability Score: 4.54 - low (50.90%) | Divividend Growth Potential Score: 5.08 - Stable (1.65%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	INR0.100	2014-09-18
Last Dividend	INR0.500	2023-06-07
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	10	--
Total Paid Out	INR1.590	--
Avg. Dividend % Per Year	0.40%	--
Score	2.2	--
Div. Sustainability Score	4.54
Div.Growth Potential Score	5.08
Div. Directional Score	4.81	--

Next Divdend (Est)
(2025-03-25)

INR0.618 Estimate 3.11 %

Dividend Stability

0.25 Very Poor

Dividend Score

2.20

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR0.0500	0.16%
2019	INR0.0500	0.18%
2020	INR0.100	0.58%
2021	INR0.250	0.41%
2022	INR0.250	0.41%
2023	INR0.500	0.85%
2024	INR0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
SHANTIGEAR.NS	Dividend Junior	2023-07-11	Annually	23	1.02%
MANGCHEFER.NS	Dividend Junior	2023-09-18	Annually	17	1.18%
GRANULES.NS	Dividend Junior	2023-08-03	Semi-Annually	20	0.29%
BAJAJCON.NS	Dividend Junior	2023-08-02	Annually	14	2.26%
TTKPRESTIG.NS	Dividend Junior	2023-07-21	Annually	20	0.43%
PLASTIBLEN.NS	Dividend Junior	2023-06-23	Annually	18	1.26%
JKTYRE.NS	Dividend Junior	2023-07-27	Annually	17	0.91%
DIAMONDYD.NS	Dividend Junior	2023-07-27	Annually	7	0.06%
360ONE.NS	Dividend Knight	2023-07-28	Semi-Annually	6	2.85%
SOMANYCERA.NS	Dividend Junior	2023-08-18	Annually	23	0.39%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.151	1.500	6.98	10.00	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0.174	1.500	9.17	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	48.41	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	2.96	2.00	9.01	10.00	[0 - 30]
freeCashFlowPerShareTTM	2.96	2.00	8.52	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.519	1.000	4.69	4.69	[0.2 - 0.8]
operatingProfitMarginTTM	0.203	1.000	7.95	7.95	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				4.54

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	24.58	1.000	7.62	0	[1 - 100]
returnOnEquityTTM	0.174	2.50	9.47	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	2.96	2.00	9.01	10.00	[0 - 30]
dividendYielPercentageTTM	0.290	1.500	2.74	0	[0 - 0.4]
operatingCashFlowPerShareTTM	2.96	2.00	9.01	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.878	1.500	7.48	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0639	1.000	-0.904	0	[0.1 - 0.5]
Total Score				5.08

Marksans Pharma Limited

Marksans Pharma Limited, together with its subsidiaries, engages in the research and development, manufacturing, marketing, distribution, and sale of generic pharmaceutical formulations worldwide. The company offers products in the analgesics, benign prostatic hyperplasia, antidiabetic, epilepsy, anti-inflammatory, hyperparathyroidism, diabetes, antacids, neurology, cardiovascular, hormonal, oncology, gastroenterology, antidiabetic, pain management, gynecology, antibiotic, antifungal, antiulceratives, vitamins, dermatology, cephalosporins, injectables, anti-allergy, antibacterial, and hypertension therapeutic areas. It also provides contract research and manufacturing services. Marksans Pharma Limited was incorporated in 1992 and is headquartered in Mumbai, India.